gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE · BDXHealthcareSurgical Instruments

Becton, Dickinson and Co. (BDX)

$209.19+5.56%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$198.17▲ 11.77% in range
Nov 3, 2025Low $140.71 · High $210.02Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Becton, Dickinson and closed at $209.19 on Nov 4, up 5.56%, 0.4% below its 52-week closing high. Volume of 4.5M shares was 2.80× its 20-day average (well above normal).

Split-adjusted performance: +16.0% over one month, +44.5% over six months, +18.0% over one year.

In the quarter ended Jun 30, 2026, revenue was $4.98B, up 5.4% from a year earlier, with a net margin of 7.6%.

Short interest was 8.9M shares at the Oct 15 settlement, down 8.9% from the prior report (3.2% of float, 5.5 days to cover).

Market cap$56.98B272.4M shares
Revenue · quarter$4.98B+5.4% YoY
Diluted EPS$1.37−31.5% YoY
P/E · TTM60.6×P/S 2.7×
Net margin7.6%Gross 46.5%
Dividend yield2.01%$1.05 last paid
52-week range140.71 – 210.02−0.4% from high
Volume4.5M2.80× 20-day avg
Volatility · 60d24.4%Annualised
Short % of float3.2%5.5 days to cover
Net cash-$16.10BCash $709.0M
Next earnings—Not scheduled
Split-adjusted performance
1W +7.2%1M +16.0%3M +18.1%6M +44.5%YTD +7.8%1Y +18.0%3Y −16.7%5Y −14.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum79
Revenue growth38
Net margin71
Value (low P/E)17
Size97

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →
Shares short8.9M−8.9% vs prior
Days to cover5.5Settled Oct 15
% of float3.2%
Short vol. 10d35.4%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
BDXBecton, Dickinson and$209.19+5.56%+44.5%+5.4%7.6%60.6$56.98B
BSXBoston Scientific$45.82+5.33%−18.2%+1.4%11.3%19.0$66.40BCompare
MDLNMedline$40.35+18.36%−4.0%—0.8%—$35.40BCompare
RMDResMed$240.51+5.91%+14.7%+5.9%29.6%21.2$33.83BCompare
DXCMDexCom$88.48+6.64%+46.6%+11.2%20.5%33.3$33.00BCompare
MMM3M$193.95+9.55%+32.4%+1.0%20.9%28.3$100.02BCompare
WSTWest Pharmaceutical Services$408.78+0.44%+30.8%+8.7%24.5%44.6$28.48BCompare
SYKStryker$339.65+9.37%+16.2%+7.6%11.5%36.0$130.28BCompare
SOLVSolventum$89.35+5.42%+25.9%+2.2%4.2%10.6$15.21BCompare

News about Becton, Dickinson and

All news →
BDX Gears Up to Report Q4 Results: How to Play the Stock?Zacks Investment Research · 1d agoNeutralBecton Dickinson (BDX) Earnings Expected to Grow: Should You Buy?Zacks Investment Research · 6d ago▲ PositiveBDX Stock Gains 25.5% in Six Months: What's Behind the Rally?Zacks Investment Research · Oct 22, 2026▲ PositiveWill Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research · Oct 9, 2026▲ PositiveBDX Expands U.S. Manufacturing With $19B Healthcare InvestmentZacks Investment Research · Oct 7, 2026▲ Positive

Quick answers

What does Becton, Dickinson and do?
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products.
What is BDX's market cap?
$56.98B, based on the Nov 4 close of $209.19.
What is BDX's P/E ratio?
60.6× trailing-twelve-month earnings of $941M.
Does Becton, Dickinson and pay a dividend?
Yes. The latest regular dividend was $1.05 per share (ex-date Sep 9), an annualised yield of 2.01%.
How much of BDX is sold short?
8.9M shares, 3.2% of float, as of Oct 15, 2026.
What sector is BDX in?
Healthcare, in the Surgical Instruments industry.

About Becton, Dickinson and

Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.

HQ: Franklin Lakes, NJ72,000 employeesListed Sep 25, 1963bd.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology